KRAS and colorectal carcinoma: Moreover, when we silenced UBQLN2 in a panel of CRC lines that expressed KRAS-WT or KRAS-Mutant, we observed reduction in the viability of the KRAS-Mutant lines but not KRAS-WT lines (Figure S7A).